univers coverag
calendar event
fda adcom bone reproduct urolog drug
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
cvs-aet jan anti-trust medacorp call insight least shade
bottom line conduct bull bear debat anti-trust scrutini associ
aet deal two medacorp specialist see deal less probabl
respect appropri structur remedi address region overlap medicar
part doj like regulatori arbit debat clearli drove home
case least fifti shade grey specialist agre benefit consum
heart anti-trust debat effici argument less convinc moreov opportun
combin op -aet mp entiti skirt medic loss ratio floor key consum
protect benefit sharehold import area regulatori scrutini anti-
competit standpoint impact vertic deal small mid market insur market seen
specialist crux debat rather detriment impact restrict retail
pharmaci network choic manag care perspect expect outcom depend
stanc doj new head makan delrahim influenc trump administr
specialist differ magnitud relev att/twx agre court
decis att/twx april key catalyst tip scale least show hand
doj regard previou manag care puls call note evolv payor drug benefit
competit landscap avail follow link
conduct puls call two anti-trust legal specialist aet deal
bull bear medacorp debat point least shade grey anti-trust scrutini vertic
cvs-aet deal doj pois lead process rather ftc
heart matter question benefit consum specialist express
skeptic potenti effici transact
impact deal abl skirt floor key consum protect
legisl obamacar view meaning area anti-trust scrutini specialist
anti-competit argument center around possibl rais cost pbm
offer small mid market health insur rival
deal view like rais barrier entri smaller mid market region health
insur given unabl compet optum absent in-hous pbm scale
like also need build ambulatori care deliveri servic time compet
minut clinic optum
restrict pharmaci network higher retail pharmaci price pbm seen far less anti-
competit concern regul
att/twx seen relev bear bull specialist though view decis
march court case extrem relev decis
similarli anti-competit impact deal independ pharmaci view deal killer
despit voic enjoy dc
futur price postur post build ambulatori urgent primari minut clinic
view less compel barrier close point exhibit
similarli futur entri even larg player drug suppli chain view unlik
influenc regulatori outcom though anoth simultan larg deal two regulatori
hopper potenti ci op op wcg op potenti vertic
deal mp wcg could materi influenc potenti even harm
decis
regulatori review estim chanc approv
bottom line last week host medacorp puls call cvs-aet anti-trust scrutini look
 featur two anti-trust lawyer discuss likelihood
op aet mp merger gain regulatori approv becam interest debat
one specialist appear confid deal would gain regulatori approv
skeptic confirm specialist view know recent file doj review
propos merger believ like deal go length regulatori review
process doj estim chanc deal ultim approv
instrument drive drug price red oak jv pbm solut
util narrow network led consider competit pharmaci space retail rate
declin seek contract plan fewer believ newco
focus achiev cost-sav ultim benefici consum horizont concern
exist part space believ allevi divestitur
harm consum harm competitor focu regulatori review
reduc retail rate rais
effici one aspect anti-trust argument
regulatori approv process underway doj charg
view att/tim warner case differ cvs/aet deal
horizont concern stick point like spur divestitur
believ pbm retail pharmaci market grown increasingli competit
anoth deal announc market regulatori approv less certain
takeaway investor confer day
bottom line note provid takeaway day competitor confer
highlight pre-announc announc
new ceo bring strong oper execut background lastli got increment
updat teva
posit pre-announc posit
sale beat expect guidanc came slightli consensu
howev ph data remain track posit
new ceo bring strong oper background howev unclear aggress
leverag balanc sheet chang strateg direct compani
heard mostli increment updat ceo paul campanelli
continu transform rare diseas focus specialti pharma compani
teva ceo kare schultz provid increment updat restructur plan outlin decemb
bottom line view top-lin data aldr chronic migrain studi promis
repres best case scenario along ip settlement equiti financ help
put number controversi rest howev given feel mute stock reaction
today news aldr share close day think investor may
focus one remain key controversi stock specif address morn
announc name aldr abil carv market intraven iv product
context multipl compet subcutan sc product howev chronic migrain data
look nomin better compet sc product almost metric reaffirm confid
eptinezumab valu proposit aldr strategi market promis eptinezumab continu
trend set promis produc meaning benefit within first day dose although
eptinezumab compet cgrp develop migrain prevent feel
mani patient make choic tri class medicin migrain episod reson
medicin clinic demonstr rapid onset effect secondli consist
first phase promis data highlight meaning number super respond
respons rate degre seen compet sc dataset final compon
continu believ buy-and-bil payment process provid tailwind launch
iv product market current pervad headach treatment center accustom payment
model experi botox new model includ increas probabl
success eptinezumab royalti cash payment owe teva
prefer share financ reiter op aldr
revenu mm ep present
bottom line today asnd releas initi safeti toler exploratori efficaci data
transcon parathyroid hormon pth hypoparathyroid addit updat transcon
growth hormon hgh growth hormon defici transcon c-type natriuret peptide/cnp
achondroplasia provid asnd aim achiev infusion-lik pth releas result
healthi adult establish pk half-lif hour vs hour natpara half-
life found serum-calcium increas dose-respons manner potenti renal calcium
reabsorpt effect transcon pth report data consist infusion-lik pth releas
adopt transcon pth beyond natpara shpg nr remain seen among endocrinologist
could extra cautiou base sub-par data natpara gener approv full data
transcon pth expect asnd plan directli enter meanwhil
transcon hgh height trial well-receiv exceed target enrol subject
top-lin result expect flight trial switch daili hgh weekli hgh anticip
complet enrol parallel transcon anticip initi data
asnd report top-lin data consist pth infusion-lik releas
reiter buy opportun volum reflect ahead
bottom line reiter outperform rate recommend buy
recent pullback despit revenu beat pre-announce investor concern
stock weak larg driven test quarter vs street estim in-
line result appear disconnect string quarter report test well
street estim met manag subsequ point
reflect quarter effort underway includ upcom sale rep hire outsid
insid rep electron order larg hospit system hire believ action could deliv
upsid beyond view in-lin consequ last week
quarter coincid holiday strong weather result remain confid
estim could prove conserv
new rep hire deliv beyond
cologuard sale ramp remain under-appreci re-ord rate signific room
improv level
larger healthcar system electron order essenti broader market penetr physician
order electron
system provid like prescrib cologuard order improv perform metric
bottom line remain outperform believ lower sequenc cost
competit among custom continu drive novaseq product upgrad cycl
share move higher compani revenu pre-announce came
 well street estim novaseq shipment
quarter total full year instal reach driver beat consum
grew y/i driven novaseq consum reaffirm prior view novaseq
consum drive meaning upsid estim steady-st novaseq pull-
like exceed per instrument link also guid
revenu ep vs estim street estim
respect still conserv includ benefit tax reform
also announc mini-benchtop sequenc meant small lab individu research call
iseq addit nextera flex product partnership op ampliseq
technolog posit view
signific increas novaseq consum highlight view novaseq pull-through
novaseq ship high-throughput custom order novaseq
consum genom inflect point opportun still ahead
clinic market tip adopt curv
iseq expect facilit small scale experi nextera flex expect help eas
posit pre-announc posit
bottom line competitor confer morn pre-announc result total revenu
in-market product compani announc expect total revenu fall within
guidanc manag also state xyrem expect revenu fall within
guidanc rang posit note manag highlight believ slowdown
refil fulfil seen second half return normal level expect volum
growth back histor low-to-mid singl digit rang strong out-performance also
seen vyxeo manag expect report high end guidanc
rang continu view one top pick near-term xyrem oper perform
look back track strong perform vyxeo near-term pipelin develop low
sodium xyrem potenti busi develop
mix result product upsid tax legisl
catalyst-rich year
ceo zubretski jan street debut music ear new pt
 methodolog normal ep
bottom line view ceo zubretski debut messag competitor confer music
ear rais pt pt reflect price-to-earnings current ep
consensu revenu view focu margin expans normal
margin target rang appropri strategi turnaround reaffirm view
ceo appoint post experi aet cfo right decis compani
ceo expect declin revenu near term follow stabil intermedi term
compani return target margin return growth commentari around time
return normal margin also larg consist expect end year
run rate margin year confid well estim meaning
street revenu street margin ep given focu go forward
margin membership updat model report
ceo zubretski focu margin membership gain revenu music ear
margin expans expect combin exit unprofit actuari unsound
busi improv contract hospit provid introduc specialist referr
standard manag care techniqu util manag well save
workforc reduct bring administr cost base closer peer averag
comfort consensu margin consensu revenu estim given
focu new manag
galapago collabor add valid novel rna edit platform
bottom line today proqr announc plan leverag fully-own axiom edit
oligonucleotid eon technolog collabor galapago glpg nr clinical-stag
biotechnolog compani long track record clinic develop identifi biolog
target design therapi fibrot diseas arrang first proqr
add valu compani combin proven leadership clinic develop
novel rna edit platform may broad applic field fibrosi addit
convers manag provid updat proqr clinic pipelin
collabor glpg posit proqr favor competit fibrosi pipelin
detail collabor releas meaning progress
partnership could potenti set futur revenu stream proqr form licens fee and/
novel therapeut product
four major program look earli proqr
guidanc show tax reform payoff hard complain
averag price-to-earnings p/ dcf methodolog
bottom line regeneron today pre-announc in-lin us eylea sale provid
expens guidanc consensu expect estim higher-than-
anticip expens result new expand acceler develop timelin
dupilumab cemiplimab also announc today conjunct
partner sanofi sni op specif partner agre co-fund addit
clinic trial primarili use lung cancer develop higher expens
almost complet off-set cash flow valuat basi compani new
expect pro forma tax rate compar consensu expect
see effort posit pull forward drug launch label expans
relat revenu growth potenti year sale growth matur eylea
reiter outperform rate price target regeneron stock
eylea net sale consensu
tax rate reduct offset valuat hit increas expens
revenu mm dilut ep non-gaap
second gx copaxon like approv posit
bottom line momenta nr provid today updat expect glatopa gener
version teva copaxon recal call momenta state expect fda
approv glatopa late earli could still possibl momenta plan
approv launch still possibl base case scenario copaxon
assum glatopa enter market march point appear launch
like come later expect would present upsid current mp
teva number
gener copaxon make progress howev appear slightli delay versu prior
upsid like teva although difficult estim magnitud impact
bottom line today report preliminari result rais guidanc
report unaudit revenu y/i beat estim
y/i street estim revenu impella product expect
y/i line estim manag rais revenu
guidanc impli revenu growth
oper detail provid expect oper margin previous
guid acceler growth profil reinforc belief well track exceed
goal revenu compani need deliv low-to-mid
compound-annual-growth-rate reach sale regardless quarterli result reinforc confid
strong double-digit long-term growth trajectori beat rais stori forese futur
stock trade posit pre-announce guidanc rais come
high believ ahead specul beat coupl million
bottom line morn pre-announc ampyra revenu
higher consensu estim respect howev
sale guid lower consensu estim
respect lower guidanc impli greater impact ampyra gener
previous appreci us street quarter also monet ampyra
selincro royalti sold zanaflex compani anticip initi
fda respons inbrija nda submiss parkinson diseas feb
continu anticip potenti approv share strong friday
heel wsj report compani may explor sale unclear us whether pre-
approv deal would maxim valu given known risk associ review drug-devic
clean data valid wart oppt bolster confid
bottom line morn announc posit phase result solut
patient common wart cw two separ trial efficaci safeti
data two report trial consist previous report phase data increas
confid ph success approv first fda-approv therapi cw
result today announc increas probabl success
previous bump dcf-base price target management expect
initi phase trial two import jak inhibitor clinic updat
two phase proof-of-principl topic jak inhibitor trial treatment alopecia
areata aa read reiter op rate
bottom line adap provid sever updat morn includ initi safeti data two on-going
phase studi lead proprietari tcr program target one non-smal cell lung
cancer nsclc second tripl tumor studi bladder melanoma head neck cancer
far patient receiv transduc spear specif peptid enhanc affin
receptor cell first dose cohort studi nsclc studi tripl tumor
studi evid toxic relat off-target bind alloreact observ well
neurotox safeti event nsclc studi seriou advers event cytokin
releas syndrom resolv treatment cohort nsclc studi expand
patient dose-limit toxic dlt observ cohort tripl tumor studi
tripl tumor studi escal next dose transduc mage spear cell
escal nsclc review follow dose patient adap reiter guidanc
provid data updat proprietari program adap also
announc progress manufactur front first spear cell manufactur navi yard
facil first dose cohort on-going multipl tumor studi agreement
cell gene therapi catapult vector product uk ensur vector suppli product
beyond on-going studi spear cell therapi afp
expect busi multipl catalyst
bottom line morn releas updat corpor slide deck refin time
sever data readout includ eagerli await dose escal result phase
sting agonist monotherapi trial second half year believ esmo
octob novemb like confer data could present
compani also announc plan discuss preliminari observ
nv mp antibodi phase trial addit expect report preliminari
biomark data phase trial pladd person live attenu double-delet listeria-
base cancer vaccin microsatellit stabl colorect cancer mss second half year
lastli initi result phase trial anti-april antibodi multipl myeloma
list mileston compani plan publish pre-clin data
bottom line outlin mileston today highlight expand clinic research
program larg line expect oncolog program track potenti
ivosidenib approv also plan initi phase trial ivosidenib plu
chemotherapi front-lin aml initi two pivot studi pyruv kinas
pk defici inhibitor phase initi mtap-delet tumor expect
ind submiss newli disclos dhodh inhibitor treatment hematolog
malign expect also revis cash guidanc suffici cash fund
oper vs end previous reflect expand program
remain posit innov platform support compani close
collabor celg op pre-announc cash equival vs
end
bottom line morn aldr announc posit top-lin data studi
eptinezumab chronic migrain patient addit compani also disclos
resolv patent disput teva via non-exclus licens give world-wide
commerci right exclud japan korea variou mileston payment deal
also includ sale royalti fund simultan announc financ agreement
point posit news morn improv stock set-up specif respect two
on-going invest controversi larg effect size look competit
better anti-cgrp antibodi settlement teva remov risk
worst-cas eptinezumab block market scenario licens deal teva could
help solidifi aldr corpor strategi regard partnership opportun also enhanc
strateg valu asset render attract view financ
agreement describ aldr access cash assum balanc
reiter op aldr
nelotanserin progress may posit import etrasimod data
bottom line axov axon nr announc trial data across intepirdin dementia
lewi bodies/ nelotanserin parkinson diseas dementia/pdd visual
hallucin program particular axov report posit trend exploratori efficaci
assess nelotanserin studi pave way potenti confirmatori trial
futur base convers investor assign much valu asset
neither therefor progress trial followed-up regulatori approv
could posit impact stock directli relev stock near-term howev
data arena second asset etrasimod moderate-to-sever ulcer coliti uc
continu posit strength reiter op
bottom line morn pre-announce sale y/i beat
estim y/i street sale come y/
ou sale y/i also guid full-year top-lin
 bracket consensu y/i high end compani continu
expect ebitda profit adjust ebitda loss come within previous guid
posit pre-announce certainli encourag support
view doubl digit sale growth profil durabl mix busi
in-lin guid believ manag exercis prudent conservat better posit
consist beat rais
bottom line post solid top-lin beat pre-announce revenue
y/i revenue growth vs consensu reiter outlook anoth year revenue
trajectori gm year continu confid abil sustain
lead posit peripher nerv repair also lead categori expand util
larg significantli under-penetrated core market opp ty uniqu barrier entri around avanc
nerv graft furthermor expect capit new market opportun breast reconstruct
neurot management estim market oppti iatrogen pain management
reiter op continu view compani one excit small-cap growth
name univers
averag method dcf price earn price sale
bottom line morn celgen pre-announc full year financi result
slightli recent lower consensu estim bottom line celgen
state total revenu line consensu estim non-gaap
ep vs consensu line forecast compani also provid
guidanc first time conserv guid lower end street total product
sale consensu non-gaap ep rang
line expect highlight present around confid
late stage pipelin hematology/oncolog inflammation/immunolog add
increment peak revenu reason behind recent announc acquisit impact
preclinci partnership focus broaden discoveri activ
bottom line today announc collabor licens agreement stemsynergi
therapeut privat discoveri develop stemsynergi preclin asset target
casein kinas alpha think neutral stock term agreement
pay stemsynergi up-front payment initi research develop
fund compon wnt signal pathway implic variou tumor includ
colorect cancer wnt signal pathway thu far proven complex difficult target
oncolog note past plan revamp intern capabl also
conduct extern bd diversifi pipelin phase result rhhbi studi
cotel tecentriq next key stock-mov event expect
earli stage progress collabor small posit
bottom line announc earn ind mileston payment antibodi target
addit extens op discoveri collabor march updat
provid continu valid earli stage discoveri capabl recal on-going
 collabor agreement exclus world-wide right develop commerci
product direct toward protein target checkpoint pathway elig receiv
futur mileston payment collabor target includ also elig
receiv tier royalti rang mid-single-digit low-doubl digit percent global net sale
product also exercis option extend research term collabor march
direct toward target two addit undisclos immun checkpoint pathway
bottom line pre-announce preliminari revenue estimate
sell day adj cc exceed upper end management guidanc rang our/consensu
think breast health bh saw signific out-performance follow diagnost out-performance
appear mostli boost better-than-expect legaci blood screen revenue partial off-set
weaker-than-expect gyn skelet health perform eye cyno qtr
deliv sale q/q vs match consensu beat
think help increas investor confid busi like bottom
pois continu improv move new leadership
sale forc stabilizes/new product launch get go reiter op
bottom line op provid latest updat membership growth expect
higher last project compani expect individu membership
grow previou estim cite higher anticip
retent exist member higher anticip sale annual enrol period
reason updat expect compani reiter group membership
growth compani also provid updat pdp membership expect
expect net declin declin membership mm
reason declin pdp membership loss auto assigne fl sc continu
membership declin enhanc lower histor level growth co-brand
plan due low-pric competit offer compani reiter adjust
ep guidanc howev expect one-tim non-cash neg impact
earn mm due re-measur defer tax asset lower enact corpor tax rate
collabor build leadership mpn
bottom line nr enter target discoveri valid collabor focus
myeloprolif neoplasm mpn collabor util gene control platform
identifi novel target focu mpn receiv option obtain exclus world-wide
right ip result collabor valid target well exclus world-wide
right develop commerci therapi modul target pay
up-front purchas common stock time collabor come
heel announc celg op acquisit impact biomedicin small posit
view approv treatment option myelofibrosi mf us think fedratinib
inhibitor may limit competit impact jakafi busi link
bottom line morn allscript announc acquir privat held practic fusion
cash view deal make sens practic fusion high qualiti asset
differenti saa platform proven manag team thought practic fusion might
ipo medium-term fact acquir asset view indic
trade immin effect remov qualiti competitor could rais signific
capit public offer sourc peg practic fusion annual revenu
link though suspect firm actual revenu may well rang practic fusion
san francisco-bas compani provid cloud-bas ehr servic small independ physician
practic tout best valu ehr practic fusion found
current support least ambulatori practic august acquir mp
enterpris inform solut ei busi includ paragon community-hospit focus
platform view addit practic fusion continu push broaden
product offer gain presenc smaller community-bas care set slightli less
penetr larger site context report decis occur
bed space schedul report earn februari
interest learn deal plan integr practic fusion
cloud-bas ehr servic current product offer
bottom line outlin goal today highlight progress two earli clinic stage
program in-lin expect antibody-drug conjug
phase dose-escal trial on-going variou express solid tumor includ breast cancer
patient score greater non-smal cell lung cancer nsclc patient express
gastric patient posit post-herceptin treatment compani
complet dose six cohort dose-escal studi maximum toler dose
yet establish plan present dose-escal data scientif confer
year pend determin recommend phase ii dose plan initi tumor-specif
dose-expans cohort phase dose-escal studi on-going w/ first
bgne deal maxim sitravatinib potenti asia small posit
bottom line beigen today announc exclus licens agreement clinic
develop commerci mrtx sitravatinib multi-kinas inhibitor asia exclud
japan australia new zealand exchang up-front mileston payment
undisclos royalti futur net sale licens territori news posit
beigen plan explor combin sitravatinib inhibitor henc maxim
commerci potenti sitravatinib sitravatinib multi-kinas inhibitor recent
gener earli yet promis phase clinic data difficult-to-treat checkpoint inhibitor refractori non-
small cell lung cancer nsclc patient link recent upgrad link compani re-
priorit pipelin program includ discontinu glesatinib develop re-alloc
resourc significantli promis sitravatinib program clinic updat program
expect
sell-off overdon over-interpret non-peer-review manuscript
bottom line intellia share react neg possibl fear immunolog
respons compani genom edit approach use upon review
said articl link relev data includ intellia preclin data believ
sell-off overdon much like previou cell articl caus fear among investor
link wherea manuscript cite import immunolog consider
drug class cite reason paper view signific neg
intellia across space reiter op
pre-announce in-lin expect
bottom line announc preliminari revenue full-year revenue
cc roughli in-lin consensu us follow last quarter
under-perform accompani substanti lower outlook think investor
hope estimate re-set would set-up beat qtr thu in-line-
with-guid revenue result -- -in soften spine market -- -are certainli step right direct
one hand come string qtli miss think result could still view
disappoint op thesi predic view overhang relat sr execut departur
slow ytd underli us spine volum larg reflect current valuat
stock trade ev/sal ev/ebitda -- -below peer despit msd revenue
growth prospect faster-than-avg profit growth potenti continu confid
new-product cycle-driven growth acceler stori plu improv margin profil
big ep step-up tap lower tax rate
bottom line morn pre-announce sale y/i mid-
point -- well ahead us consensu respect also issu
sale guidanc y/i mid-point estim
y/i in-lin consensu sale expect come
ou sale ahead us street conjunct pre-announce
also announc receiv fda approv next-gener senza ii spinal cord
stimul deliv therapi fda approv believ posit
compani potenti upsid just-issu sale guidanc think
itll take anoth quarter solid beat stock realli break pre-announce
like view posit boost investor confid execut improv
help calm fear deeper underli issu technolog
highlight acceler base busi guid need
bottom line remain outperform rate op preannouc expect
revenu hereditari base busi compar estim
hereditari genet test busi report access test also
compar posit estim despit pre-author concern combin
result acquisit expect total access test
revenu compar consensu guid volum
least sampl access believ conserv least
total revenu given limit detail around least revenu believ
like get question around detail assumpt drive revenu guid given
street model model test base hereditari busi
see guid least test combin hereditari reproduct busi
could prove conserv question like remain around asp test growth
reproduct busi loss volum
coverag grant meaning upsid like beyond
bottom line morn issu press releas announc grant
coverag omnipod coverag decis well expect believ posit
compani potenti upsid sale estim y/i
consensu recal type patient fall medicar access
type medicar patient total type patient per estim
addit secur medicar coverag also provid pathway medicaid coverag
expect bring combin medicar medicaid type patient
limit abil market patient patient would pay out-of-pocket --
burdensom prospect per year pediatr constitut larg segment instal
base believ small portion exist patient fall medicar us suggest
adopt medicar patient larg increment street model today
share meaning outperform today view posit news also
feel encourag well-posit deliv consist beat rais quarter
top line achiev sale target compound-annual-growth-rate
ahead us street compound-annual-growth-rate respect
new ceo helm
bottom line morn announc uwe rohrhoff appoint presid
ceo board member effect januari current ceo john hendrickson remain
compani march assist transit mr rohrhoff limit
experi specif consum healthcar gener strong record oper
global leadership posit bring proven record drive growth oper
complex global oper platform believ would relev context
deliv strong result last two quarter look comment
mr rohrhoff vision compani growth oper effici go forward
look potenti detail competitor confer tuesday
race cf tripl combo therapi pti endors pois
bottom line morn pti announc influenti cystic fibrosi cf pt advocaci
group develop network/tdn clinic trial network/ctn us
protocol endors high strateg fit score link pt advocaci group gain
stronger presenc clinic develop regulatori approv process op
long-standing collabor cystic fibrosi foundat help develop
orkami other op exondi approv link believ endors
could help expedit enrol execut tripl combin therapi trial pti op
op glpg nr /abbv op race get tripl combin therapi market pti plan
initi dose cf pt proof concept poc studi tripl combo therapi
us eu cf center within tdn ctn network expedit process
initi data expect parallel op edg plan initi pivot
develop tripl combo regimen top tezacraftor
ivacraftor pend addit data studi earli glpg nr /abbv op
meanwhil advanc lead tripl combin program dose expect commenc
uk interim readout reiter op
mileston in-lin expect
bottom line outlin mileston morn in-lin expect
mileston includ may pdufa action date adcetri plu chemotherapi frontlin hodgkin
lymphoma hl fda accept supplement bla januari recal supplement
bla submiss base posit phase data recent present american
societi hematolog key catalyst includ result
phase trial adcetri peripher cell lymphoma in-lin expect solid
tumor pipelin program continu advanc enfortumab vedotin enrol continu
pivot studi local advanc metastat urotheli cancer patient previous treat
checkpoint inhibitor phase ib enfortumab vedotin combin studi checkpoint inhibitor
tisotumab vedotin initi multipl phase ii studi expect recurrent/metastat cervic
cancer part combin regimen line cervic cancer solid tumor type multipl
studi initi also expect ladiratuzumab vedotin combin checkpoint
inhibitor metastat tripl neg breast cancer well neoadjuv therapi earli breast
cancer part i-spi consortium
tsro guid zejula sale us
bottom line morn tsro releas updat compani slide deck guid
zejula niraparib sale mid-point line estim consensu
repres modest increas sale report zejula
appear maintain larg share parp inhibitor market ovarian cancer
novemb base tsro chart figur growth total parp-treat patient number
chart appear moder note mani patient treat last month
like receiv agent mainten therapi result longer durat therapi
particularli brca-mut patient provid addit sale growth class base figur
tsro estim zejula patient receiv drug mainten set
bottom line preannouc today reiter guidanc revenu
compar estim consensu also announc
report test volum afirma percepta combin approxim test
line estim test beyond compani announc strateg realign
corpor structur new appoint busi creat new scientif clinic
medic affair depart appoint giulia kennedi prior cso head also appoint
jessica meng vice-president market also expand sale team sale specialist
last quarter like reflect oper expens believ compani
also reiter cash burn compar estim
see benefit tax reform
bottom line morn walgreen file brief updat anticip impact
recent tax legisl compani expect obtain cash tax benefit excess
drive favor impact adj ep note leerink/consensu
estim fy end august estim repres
approxim benefit new lower corpor tax rate impli greater save perhap
upsid estim current leerink/consensu short statement
walgreen said analysi preliminari compani plan provid updat
pre-announc guidanc come feb
vs expect revenue cc sell day adj come ahead
consensu ahead us expect management see benefit new sale forc
hire also unanticip suppli constraint relat third-parti coat
vendor affect total ankl busi accord press releas issu
address nonetheless still impact detail provid us upper extrem
solid growth lower extrem continu lag histor level albeit
expect lower extrem cc bit weak vs model us lower extrem
come higher vs think y/i growth vs model think key share
rebound depress level continu steadili improv lower extrem revenue growth
recent hire lower extrem rep hire come product curv continu
believ end-market remain healthi grow well posit
take share within drive hsd sell day adj growth rep product increas
new product launch continu gain steam -- acceler potenti low-teen
bottom line pre-announce strong top-lin beat rev rang
us/consensu y/i compani issu preliminari guidanc
bracket consensu expect view revenue out-performance initi
guidanc -- -like conserv view -- -a encourag sign ahead one biggest new product
cycl sinuva compani histori tap continu view excit small-
cap growth stori gm profil sinuva approv increas confid
compani abil drive meaning higher sale momentum beyond reiter op
encourag initi muscl result size matter
analysi discount rate termin growth rate
bottom line morn acceleron announc first phase ii patient data part
local administ muscl build agent report muscl size increas
two differ muscl site patient rare focal muscl diseas fshd met
exceed muscl enlarg effect expect compani provid reassur
associ improv muscl strength function patient
muscl fat reduct rel modest muscl volum increas reassurin given
short durat therapi complex multipl local inject muscl
bodi lack posit commentari function effect disappoint acceleron
never plan formal test function placebo part look trend
strength function test deliber avoid comment result press
releas muscl size increas encourag proof concept unless accompani
improv strength function drug still doesnt much futur except perhap
cosmeceut result suggest us investor view program
risk chang immedi futur appear part result studi
like announc mani requir confirm valu
averag method dcf price earn price sale
tax reform resurg retail volum visibl pt
jan margituximab phase i/ii data gastric cancer
margetuximab evalu phase i/ii keytruda combin studi second-lin
gastric cancer enrol expect complet clinic data
expect asco-gi jan
management indic respons rate bar advanc combin
project margetuximab probability-weight breast cancer gastric cancer
sale
margetuximab ph interim futil analysi earli
tezacaftor/ivacaftor pdufa date homozyg offer improv
toler profil orkambi potenti approv offer underappreci volum
find vertex tez/iva potenti approv low-risk meaning catalyst
vertex sinc combin improv toler profil increas penetr
orkambi exist indic enabl re-treat prior discontinu
management describ tezacaftor/ivacaftor potenti approv greatest near-term driver
investor could also benefit confirm develop timelin vertex novel
tripl combin therapi begin pivot trial could result
phase dose escal interim safeti data expect earli
recal dose escal on-going variou express solid tumor includ
breast cancer patient score greater nsclc patient express
gastric patient posit post herceptin treatment
risk step given antibody-drug conjug fail due toxic concern
particular thrombocytopenia neutropenia gi toxic ocular advers event
pend determin recommend phase ii dose plan initi four
cdtx rezafungin iv phase ii data candidemia
phase ii strive data rezafungin iv system candida infect
expect
cdtx share sold significantli earlier topic program
vulvovagin candidiasi discontinu think perceiv read-through
error continu ascrib odd approv underlin robust pharmacokinet
preclin safeti histor echinocandin data
project probability-weight rezafungin sale
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab would
attract altern cytotox standard-of-car follicular lymphoma fl
analysi commerci opportun confer augment suggest success
worth per share
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
derm phase data acn
top-lin data expect two ph trial
high level convict derm topic acn program stem clinic valid
robust efficaci data ph iib studi highli power ph program pois
deliv definit result pt medacorp kol check support
strong reimburs access uptak prospect given uniqu on-target
mechan action
project probability-adjust sale
hyperhidrosi excess sweat pdufa probability-of-
follow recent success complet futil analysi ph
studi aneurysm subarachnoid hemorrhag asah patient pivot event
edg share set in/around compani conduct interim analysi
see binari event upsid skew risk/reward
compar vs standard care oral nimodipin asah
succeed interim analysi need better oral nimodipin
base case assum odd success
project probability-weight sale
ionis-httrx phase ib data huntington diseas
ionis-httrx phase ib data earli albeit under-follow clinic event
think could offer import proof-of-principl antisens strategi huntington diseas
signific unmet medic need hd repres massiv potenti market
opportun novel disease-modifi strategi
upcom httrx result import potenti roch
also see meaning read-through op whose antisens hd program also
phase ib month behind
project ionis-httrx probability-adjust sale eu
receiv mid-teen royalti
sourc leerink research compani inform factset price prior day
fda adcom bone reproduct urolog drug
nerlynx neratinib meet ema scientif advisori group oncolog
state union address
fda adcom joint meet anesthet analges drug product
drug safeti risk manag
pdufa peg-pal phenylketonuria tezacaftor/ivacaftor cystic
fda adcom neurolog devic panel medic devic evalu clinic
data intracrani aneurysm treatment devic
pdufa akao plazomycin complic urinari tract infect bloodstream
american associ hand surgeri
plant anim genom
societi thorac surgeon
societi matern fetal medicin pregnanc meet
american colleg radiat oncolog
societi laboratori autom screen
associ access medicin
advanc genom biolog technolog
european crohn coliti organis
advanc technolog treatment diabet
american academi dermatolog
bmt tandem meet american societi blood marrow transplant
asbmt center intern blood marrow transplant research cibmtr
societi critic medicin sccm
pittsburgh confer analyt chemistri appli spectroscopi
european congress radiolog ecr
american academi allergi asthma immunolog aaaai /wao
confer retrovirus opportunist infect
intern confer target anti-cancer therapi tat
healthcar inform manag system societi himss
american academi orthopaed surgeon aao
 first apprais tax offer small benefit
manag insur fee moratorium meaning upsid mco
manag floor unintend consequ tax reform aet-cv
 tax cut tailwind exchang rate
hcit distribut senat approv tax reform reconcili hous
 aet creat new front healthcar outperform larsen david
manag cvs-aet neutral ep wcg ci
gupt ana
 aet seek creat new low-cost community-bas model
-- flash /aet may closer deal combin would creat signific
manag -- flash cvs-aet like dec per share mix
equiti question gupt ana
aet -- flash anoth rais pbm qs
 volum start show improv respond aggress
manag aet offens defens consum deal
 aet bring comprehens member
-- flash dementia psychosi btd po surpris basket high risk/
aciu kol lunch support target tau ad interim look advanc
aciu recap pipelin w/ new antibodi select cren
aciu -- flash aciu receiv chf roch phase initi anti-
 aducanumab titrat arm bolster evid treatment effect market
 ctad medacorp call aducanumab abeta hypothesi
 lp hic panel controversi focu ahead data
 roll new ttr model updat spinraza pipelin pt market
 synergi specialti purchas aggress medic manag
hcit distribut outlook increasingli competit suppli chain shift
hcit distribut amazon estim matter
hcit distribut wholesal licens may start hub spoke
hcit distribut enter brick mortar space pbm deal could
hcit distribut like take modest size step pharmaci
manag entri drug distribut chain
healthcar distribut suppli chain preview price volum trend
manag -- flash marriag aet jilt altar toward
optum wanna-b
-- flash comment stir lab suppli busi back
controversi focu ahead drug launch
futur major invest theme backdrop clinic risk
-- flash fourier result chang standard cv patient
 fourier lift statin throne plausibl like
 set new slow-growth outlook get excit pt
biopharma -- flash trulic sustain blow sema must show cv benefit
biopharma -- flash bydureon fail show cv benefit posit novo
biopharma -- flash highlight invokana fda warn puls call modest
impact
biopharma leerink confer offer first mani face offswil
 model updat reflect goal achiev w/ pipelin success market
mdco anoth step forward cubist vabomer approv pt
novob dc evolut market make pivot year novo
view market perform
nv -- flash canto suggest role ilari cv uptak reimburs may
nv -- flash surpris win canto hit primari endpoint await
biopharma ada day takeaway healthcar focu canva
biopharma -- flash highlight invokana fda warn puls call modest
impact
biopharma -- flash jardianc win lose wake invokana
medic suppli devic abt/mdt secur approv diabet devic
medic devic cgm libr impact market uncertain still oversold
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-
novob dc highlight nvo management roundtabl boston market perform
view market
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
 slow growth outlook price power reced upsid limit pt
biopharma dupix approv price test new paradigm drug access
 volum price pressur continu reduc estim market
esrx aggress price loss competit market pt market
hcit distribut fda take step improv competit distributor near
hcit distribut rx distribut channel wood
 dupix price valu money new
tsro zejula price prompt model valuat updat pt lower
 medacorp call gener posit sinuva reimburs prospect
biotechnology/aan recap sma steal show migrain epilepsi pd psych
 american academi neurolog planner
 futur major invest theme backdrop
 neurosci panel takeaway leerink global
 outlook smid biotech theme rnai/antisens id
gwph qtr recap dinner physician bullish uptak ahead
gwph/aan presentation/kol event -- epidiolex profil continu look favorable/
 build solid foundat xlh data could posit ahead
gwph lower pt better data setup still solid
 own dont part wake
-- flash kol call po risk/benefit support major role orphan
 lp hic panel controversi focu ahead data
biopharma lp hic heme-onc panel point rise car-t treatment nhl
biopharma lp hic breast/ovarian cancer panel highlight pot parp
 takeaway nash panel
management dinner offer perspect pdp launch/strategi
 management dinner offer perspect pdp launch/strategi potenti
-- flash dementia psychosi btd po surpris basket high risk/
re-fil inbrija nda parkinson diseas episod believ issu
 kol dinner offer insight emerg drug psych
 recap sma steal show migrain epilepsi pd psych
 upgrad op overhang remov shot base fda/cn
biopharma name shame california latest strategi rein drug
 price sensit analysi show path share upsid pt
healthcar distribut suppli chain preview price volum trend
hcit distribut brand inflat top show deceler y/i
cautiou
hcit distribut volum price appear cautiou suppli chain
ahead earn
 elast demand consist reduc price drive volum growth
mdco payor survey explor elast price outcom data
pharmaci benefit manag pbmi confer take-away pbm right
side price debat
 hemophilia panel takeaway leerink global healthcar
biopharma -- flash highlight io combin seri puls call front-lin
biopharma highlight io agonist checkpoint puls call updat
biopharma highlight immuno-oncolog kol discuss
biopharma takeaway io remain major area focu
io clinic trial updat crossroad effici
biopharma catalyst tracker busi year ahead neuro oncolog inflamm
biopharma io combo panel takeaway leerink global healthcar
 deep dive highlight oncolog focu strategi nash market perform
 adcetri deep-div highlight upside/downsid pt
 patent fall hurdl humira cut like pipelin loom
achn recap increment advanc patent complement
acr/ patent issuanc enhanc lt valu could add npv
 patent strategi come focu mitig biosimilar risk outpfrm
 doubl extend patent horizon tecfidera
 took money ranminim valu uplift us patent win
 tecfidera settlement hedg downsid scenario known larg
biopharma cafc oral argument justic challeng scope ab patent
biopharma regn/sni appeal brief strong case cafc buck
 injunct offer upsid downsid
 patent issuanc reflect execut strategi pt outperform
 recap data ip progress uk/eu mark new year
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg qed ged late stage failur throw ibd bd
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
achn partnership termin push cfd inhibitor main stage pt
aesthet devic -- flash purchas zltq valid ni fat market
aesthet devic talk heat aesthet
 quiet focu remain pot ibs-c partnership catalyst
biopharma viii partnership acquisit biopharma new top list
 aet bring comprehens member
cori posit updat donepezil pilot studi possibl partnership ye
dplo mid-mkt pbm acquisit complet strateg move market perform
 insight jan investor dinner former aet ceo
 outperform
pthn downgrad market perform pend acquisit pt
 add cscc respons diseas boost /sni
 refin model reflect acquisit detail outperform
 updat model reflect patheon acquisit pt outperform
-- flash partner drug advanc phase outperform
 celg defend celgen could
self-help stori
 discuss deep dive alks/itci test fda flexibl
alny/ion ttr amyloidosi physician survey
 gwph major takeaway weekend annual
epilepsi meet
 analyst event best idea
share teva tourett look better
outperform
healthcar leerink outlook
manag convers
 look diamond rough initi coverag
spec pharma/gener
-- contact leerink repres detail access podcast
biopharma us biopharma product updat lli premium us
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight breast cancer kol discuss
biopharma highlight lung cancer kol discuss
biopharma highlight asthma/copd kol discuss
biopharma highlight immuno-oncolog kol discuss
biopharma highlight myeloma kol discuss
window rival
biopharma highlight heart failur kol discuss
aldr -- flash management dinner includ discuss product differenti ip im/
-- flash takeaway investor dinner rais stori intact
biopharma io combo panel takeaway leerink global healthcar
 hemophilia panel takeaway leerink global healthcar
 neurosci panel takeaway leerink global
hcit distribut leerink confer panel highlight rx suppli chain
healthcar summari leerink global healthcar confer
medic suppli devic leerink confer panel highlight three
adap -- flash addl respons seen tcr synovi sarcoma updat
-- flash event highlight potenti sting activ
biopharma -- flash olympiad data solid gbrca breast lynparza benefit may
driven
biopharma xclips xtandi hope get stampede-d
 day takeaway data focu among emerg
-- flash bcma car-t continu outperform
-- flash event highlight data myeloma
-- flash event focus emerg target biomark strategi
 encourag earli updat outperform
cldx -- flash glemba get harsh review discuss varli nivo data
-- flash increment cotel melanoma updat asco bode
-- flash grail highlight earli ctdna data liquid biopsi start gain
imdz -- flash continu show favor os await combo data
imdz -- flash phase radiat data show abscop effect follicular
juno -- flash emerg profil dlbcl look promis pivot trial
-- flash data solid w/ manag diarrhea
-- flash highlight investor event broad keytruda
major io lung cancer highlight win battl
small dataset
 add cscc respons diseas boost /sni
-- flash updat support strong profil dev bladder
tsro -- flash topacio show encourag initi orr zejula keytruda
 mix outlook physician survey regard intrarosa
 pbc survey suggest ocaliva safeti concern manag
 survey payor concern plan upset orphan
 rubraca posit base survey lower est due payer
facil
medic suppli devic survey surprisingli posit trend support
 physician survey support nerlynx opp ty breast cancer pt
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leadership seri call highlight foundat improv growth ahead
 leerink leadership seri new product growth acceler stori
medic devic leerink leadership seri bigfoot brink disrupt
medic devic leerink leadership seri outset drive shift dialysi self-
medic devices-cardiolog leerink leadership seri target
 leadership call offer insight multipl hot topic controversi
healthcar outlook healthcar invest opportun year chang
